Clinical trials: Molecular Targeted Therapies
Pancreas Cancer
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence…
- Trial name
- PROTECT-PANC (NCT06228599)
- Testing
- Treatment Plan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Breast Cancer Female
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
An open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where the primary endpoint of the study is to…
- Trial name
- NCT05376644
- Testing
- 99mTc-ADAPT6, 99mTc-DARPinG3
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Nasopharyngeal Carcinoma
Anrotinib and Tirelizumab in First-line Treatment of RM-NPC
This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05981157
- Testing
- Anrotinib plus Tirelizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Non-Small-Cell Lung Carcinoma
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
This study will investigate the effects and side effects of BAY 43-9006 in patients with advanced, recurrent, or refractory non-small cell lung cancer (NSCLC).
- Trial name
- NCT00098254
- Testing
- BAY 43-9006 (Sorafenib)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma, Molecular Targeted Therapy
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma
This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma.
- Trial name
- NCT04642547
- Testing
- Lenvatinib and Gefitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
Non-intervention observation to evaluate the safety and efficacy of immune checkpoint inhibitors alone or combined with molecular targeted drugs / local interventional therapy in patients with advanced liver cancer, and to…
- Trial name
- NCT05609695
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
Tumor-draining lymph nodes play an important role in anti-tumor immune responses. In patients with hepatocellular carcinoma (HCC), however, the relationship between regional lymph node metastasis (LNM) and immunotherapy-based…
- Trial name
- CHANCE2421 (NCT06876753)
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhongda Hospital
Solid Tumor, Metastatic Cancer
A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre
The project, called "BALLETT" (Belgian Approach of Local Laboratory Extensive Tumor Testing), has a double goal: (1) show the relevance of broad molecular profiling to improve oncological patients care, (2) demonstrate that broad…
- Trial name
- BALLETT (NCT05058937)
- Testing
- Comprehensive genomic profiling
- Where
- 12 sites in Belgium
- Volunteers
- 936 people
- Sponsor
- The Belgian Society of Medical Oncology
Advanced Breast Cancer
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial
plasmaMATCH is a multi-centre phase IIa umbrella trial platform consisting of a ctDNA screening component and a therapeutic component.
- Trial name
- plasmaMATCH (NCT03182634)
- Testing
- Fulvestrant, Neratinib, AZD5363
- Where
- 19 sites in United Kingdom
- Volunteers
- 1,150 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Brain Tumor, Brain Tumor, Recurrent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease.
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric
- Trial name
- NCT04023669
- Testing
- Prexasertib, Cyclophosphamide, Gemcitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging
CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma
⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients.
- Conditions
- Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence, GMP-compliant Radiopharmaceutical Preparation
- Trial name
- NCT07280793
- Testing
- BCMA-Targeting CAR-T Cell Therapy, PET/CT Imaging
- Volunteers
- 10 people
- Sponsor
- Xuzhou Medical University
Recurrent Melanoma, Stage IIIA Melanoma
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02094872
- Testing
- cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Advanced Cancer, Solid Tumor
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used…
- Conditions
- Advanced Cancer, Solid Tumor, Haematological Malignancy
- Trial name
- FINPROVE (NCT05159245)
- Testing
- Alectinib, Cobimetinib, Vismodegib
- Where
- 5 sites in Finland
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)